Background Real‐world data describing outcomes of treatment among metastatic renal cell
carcinoma (mRCC) patients are limited and heterogeneous. Aim RENSUR3 registry study …

Background The 5-year overall survival (OS) of patients with metastatic renal cell carcinoma
(mRCC) has been rarely reported. The aim of the RENSUR5 registry study was to obtain …

20 Background: The results of the 5-year overall survival (OS) in patients with metastatic
renal cell carcinoma (mRCC) has been reported rarely. The aim of the RENSUR5 registry …

Background Patient characteristics and survival outcomes in randomized trials may be
different from those in real-life clinical practice. The objective of this study was to describe …

Simple Summary The management of metastatic renal cell carcinoma (mRCC) represents a
clinical challenge. Progression or toxicity may occur during first-line treatments and many …

Results Median OS and one-, three-and five-year OS rates were not reached and 88.7%,
64.9%, and 64.9% in patients treated in 2016-2020; 31.4 months and 78.5%, 42.8% and …

Background The current available evidence on the management of metastatic renal cell
cancer (mRCC) in real life is scarce in our environment. We present a summary of the …

Introduction Treatment advances in metastatic renal cell carcinoma (mRCC) have improved
overall survival (OS) in mRCC patients over the last two decades. This single center …

Background Before the era of targeted therapies, cytokines were the main therapy for
metastatic renal cell carcinoma (mRCC). Our aim was to analyze the changes in treatments …

Background This retrospective study investigated overall survival (OS) and factors
influencing OS in Swedish patients with metastatic renal cell carcinoma (mRCC) during the …